מתוך medicontext.co.li
WESTPORT, CT (Reuters Health) – Almotriptan has good anti-migraine activity and may be better tolerated than sumatriptan, Spanish researchers report. Almotriptan received US FDA approval in May of this year (see Reuters Health report, May 8, 2001).
Dr. Jordi Gras of Almirall Prodesfarma, Research Centre in Barcelona and colleagues compared the vascular effects of sumatriptan with that of almotriptan in isolated human blood vessels. "This paper is the first to report in detail the effects of almotriptan, a selective and potent 5-HT1B/1D agonist, in preparations of isolated human blood vessels," they note in the current issue of Cephalalgia, dated October.
Almotriptan showed "selectivity of action" for the migraine-related meningeal arteries, according to the team. Moreover, "almotriptan proved to have a statistically significant, seven-fold greater potency and a greater effectiveness in contracting this vessel in comparison with sumatriptan," they report.
The two triptans had similar effects in non-migraine related cranial and extracranial vessels, the team reports. However, almotriptan had lower vasoconstrictive effects on isolated human coronary vessels, which have "putatively been linked to some adverse events in association with sumatriptan," Dr. Gras and colleagues report.
Based on this study, "one can presume that almotriptan, at the therapeutic oral dose, should be more active than sumatriptan and should possess a profile of adverse events clearly lower than sumatriptan," Dr. Gras noted in comments to Reuters Health.
"This assumption has been reinforced by the results of a triptan meta-analysis recently published [Lancet 2001,358:1668-1675], which confirms the superiority of almotriptan compared to sumatriptan in terms of efficacy [sustained pain-free and consistency] variables as well as tolerability," he added.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!